Advertisement

ICCC

ImmuCell Corporation

Healthcare · USD

Set alert

Price alert · ICCC

All alert types
10.26 USD -0.28 -2.69%
As of Oct 30, 2026 Extended hours 10.26 0.00%
Bid
10.25 × 2
Ask
10.60 × 2
9.98 Day range 10.36
4.56 52-week range 11.72
YTD
+66.83%
1 year
+68.47%
Open
10.25
Prev close
10.54
Mkt cap
93.18M
Vol
11.02K
Avg vol
18.05K
EPS
0.07
P/E
146.57
Div yield
0.00%
More statistics
Low
9.98
High
10.36
Forward P/E
-42.82
Beta
0.57
Short ratio
0.23
Inst. own
14.51%
Dividend
0.00
Ex-div date
50-d avg
3.93
200-d avg
4.28
1y target
0.00

2Y chart

Chart tools
Interval
ICCC two-year price chart3.385.567.749.9212.1Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
41.97M
Enterprise value
42.71M
Trailing P/E
0.00
Forward P/E
-42.82
PEG ratio
0.00
Price / sales
1.81
Price / book
1.46
EPS (TTM)
-0.49
Beta
0.57
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-17.44%
Revenue (TTM)
23.22M
Revenue growth
54.90%
Free cash flow
522.36K
Total cash
1.32M
Total debt
15.84M
Return on equity
-16.10%
Shares outstanding
8.91M
Short % of float
0.06%
50-day average
3.93
200-day average
4.28

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
ICCC Revenue — quarterly 7.19M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ICCC Net income — quarterly 1.83M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ICCC EPS — quarterly 0.20
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ICCC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00-0.09——
Aug 13, 2024Jun 1, 20240.00-0.20——
May 14, 2024Mar 1, 20240.00-0.06——
Feb 27, 2024Dec 1, 20230.00-0.15——
Nov 13, 2023Sep 1, 20230.00-0.12——
Aug 10, 2023Jun 1, 20230.00-0.18——

Upgrades / downgrades

ICCC analyst upgrades and downgrades
DateFirmActionFromTo
Jul 13, 2020Aegis Capitalinit—Buy

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
immucell.com

News

Your note

Sign in to keep a note on ICCC — it syncs with the Stock Master app.

Institution ownership

ICCC institution ownership
Holder% heldSharesValueReported
Cresset Asset Management, LLC2.96%264,0021.24MSep 29, 2024
Vanguard Group Inc2.53%225,5951.06MSep 29, 2024
Renaissance Technologies, LLC1.68%149,489704.09KSep 29, 2024
Bleichroeder LP1.14%101,594478.51KSep 29, 2024
Dimensional Fund Advisors LP0.82%72,682342.33KSep 29, 2024
Morgan Stanley0.71%63,516299.16KSep 29, 2024

Fund ownership

ICCC fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.78%158,957748.69KSep 29, 2024
Vanguard Extended Market Index Fund0.75%66,638313.86KSep 29, 2024
Fidelity Extended Market Index Fund0.33%29,102137.07KOct 30, 2024
DFA U.S. Small Cap Value Series0.32%28,578134.60KJul 30, 2024
Fidelity Total Market Index Fund0.15%13,74764.75KOct 30, 2024
iShares Micro Cap ETF0.15%13,12761.83KOct 30, 2024
Advertisement